Roche’s Rituxan Cures Rare Skin-Blistering Disease in Study

Roche Holding AG’s top-selling drug Rituxan effectively cured most cases of a rare and deadly skin disease in a patient study that suggests the medicine may replace steroids as the standard treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.